- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 134 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 140 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- September 2020
- 50 Pages
China
From €2366EUR$2,600USD£2,029GBP
- Report
- April 2024
- 30 Pages
Global
From €3231EUR$3,550USD£2,770GBP
- Report
- November 2023
- 262 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- April 2023
- 147 Pages
Global
From €4504EUR$4,949USD£3,861GBP
- Report
- April 2023
- 147 Pages
Global
From €4504EUR$4,949USD£3,861GBP
- Report
- March 2021
- 132 Pages
Global
From €13647EUR$14,995USD£11,699GBP
- Report
- January 2024
- 84 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- November 2021
- 620 Pages
Global
From €3640EUR$4,000USD£3,121GBP
Entecavir is an antiviral drug used to treat chronic hepatitis B virus (HBV) infection. It is a nucleoside analogue, which works by blocking the activity of the virus in the body. Entecavir is used to reduce the amount of virus in the body, reduce the risk of liver damage, and improve liver function. It is also used to reduce the risk of cirrhosis, liver cancer, and death from liver disease. Entecavir is available in both oral and intravenous formulations.
Entecavir is a widely used drug for the treatment of chronic HBV infection. It is generally well tolerated and has been shown to be effective in reducing the amount of virus in the body and improving liver function. Entecavir is also used in combination with other drugs to treat more severe cases of HBV infection.
Entecavir is marketed by several pharmaceutical companies, including Bristol-Myers Squibb, Merck, and Gilead Sciences. Other companies that market entecavir include Mylan, Teva Pharmaceuticals, and Cipla. Show Less Read more
